# A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Source: https://onco.cc/trials/nct04774718/  
OnCo record `nct04774718` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Alectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors is a phase 1/2 interventional study registered as NCT04774718 by Hoffmann-La Roche, with 42 participants enrolled, started 2021-09-14 and due to reach its primary completion in 2032-02-28. Interventions recorded: Alectinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04774718
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
- Sponsor: Hoffmann-La Roche
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT04774718: https://clinicaltrials.gov/study/NCT04774718

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct04774718.json